References
1. L.X. Yu, Pharm. Res.
25(4), 781–791 (2008).
2. T.D. Cabelka et al., "Application of Quality by Design Principles to the Formulation of aHydrophilic Matrix Tablet of
a High Dose/High Solubility Drug," presented at the AAPS Annual Meeting (Los Angeles, 2009).
3. T.D Cabelka et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Propranolol Hydrochloride
Hydrophilic Matrix Tablets," presented at the AAPS Annual Meeting (New Orleans, 2010).
4. H. Deng et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Theophylline Hydrophilic
Matrix Tablets," presented at the CRS Annual Meeting and Exposition (National Harbor, Maryland, 2011).
5. A.S. Rathore and H. Winkle, Nature Biotechnol. 27 (1) 26–34 (2009).
6. ICH, ICH Q8(R2) Pharmaceutical Development (2009).
7. USP 30–NF 25, "USP Monographs: Hypromellose," online,
http://www.uspnf.com/, accessed May 10, 2008.
8. J.E. Hogan, Drug Dev. Ind. Pharm.
15 (6), 975–1999 (1989).
9. P. Gao et al., J. Pharm. Sci.
85 (7), 732–740 (1996).
10. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci.
93 (11), 2746–2754 (2004).
11. K. Mitchell et al., Int. J. Pharm.
66 (1–3), 233–242 (1990).
12. A.R. Rajabi-Siahboomi, A. Nokhodchi, and M.H. Rubinstein, "Compaction Behavior of Hydrophilic Cellulose Ether Polymers,"
in Pharm. Technol. Yearbook: Tableting and Granulation (1998), pp. 32–40 .
13. R.W. Korsmeyer et al., Int. J. Pharm. 15 (1), 25–35 (1983).
|
